Replies to post #1559 on Vascular Biogenics Ltd (VBLT)

[davidal66]

Yea, it's weird their stock price tanked today after the release, but 6 CR's in a cluster of 56 patients is a 10 % level which is very good. On the other hand, I don't know if the inclusion criteria. For example, the stellar Duke Un. Polio viral therapy for rGBM had/has strict inclusion criteria regarding location and other rules that might skew the data towards great outcomes. CLDX also used strict inclusion criteria which is partially why the phase III trial tanked. VBLT's phase II trial design allowed a real world experience... i.e. the worst of the worse, which is strongly in their favor.